Current Edition


Lilly puts $700M into genetic medicine institute

Dive Brief: Eli Lilly is again upping its investment in genetic medicine, announcing Tuesday plans to establish a Boston research center that will use RNA- …

Continue Reading →

Editas’ executive shake up continues

Dive Brief: Editas Medicine, a biotechnology company focused on CRISPR gene editing, has fired its chief medical officer, adding to a series of executive-level change-ups …

Continue Reading →

Incyte withdraws cancer drug from FDA review after discussions with regulator

Dive Brief: Incyte is pulling its application for an experimental lymphoma medicine after determining that the Food and Drug Administration’s requirements for confirmatory studies would …

Continue Reading →

Roche revives a closely watched Huntington’s disease drug

Dive Brief: Roche has outlined a new clinical path forward for a closely watched Huntington’s disease drug ten months after disappointing Phase 3 study results …

Continue Reading →

Moxidectin gets USFDA nod to treat River Blindness

 Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) have announced that the …

Continue Reading →

Haselmeier and Common Sensing Enter Connected Injectable Medicine Collaboration

Haselmeier, a Swiss-based developer and manufacturer of innovative self-injection devices, and Common Sensing, a Cambridge-based smart injector monitoring and support solutions company, today announced a …

Continue Reading →